Skip to main content

Table 2 Association between tertiles of systemic immune-inflammation index and death in patients with and without diabetes

From: Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry

Clinical outcomes

Log-transformed SII

Tertiles of systemic immune-inflammation index

P for trend

Tertile 1 (N = 702)

Tertile 2 (N = 706)

Tertile 3 (N = 703)

 

 < 613.57

613.57–1136.56

 ≥ 1136.56

 

All-cause death

     

Overall cohort (N = 2111)

     

 Event

–

57

63

90

–

 Incidence rate (95%CI)a

–

2.95 (2.28–3.83)

3.35 (2.62–4.29)

5.23 (4.25–6.43)

–

 Unadjusted Model

2.83 (1.83–4.38)**

Ref.

1.14 (0.80–1.63)

1.75 (1.26–2.44)**

 < 0.001

 Adjusted Model 1b

2.16 (1.46–3.20)**

Ref.

1.18 (0.83–1.69)

1.74 (1.25–2.43)*

 < 0.001

 Adjusted Model 2c

1.57 (1.02–2.43)*

Ref.

1.04 (0.72–1.50)

1.54 (1.07–2.21)*

0.016

Diabetic cohort (N = 789)

     

 Event

–

25

32

39

–

 Incidence rate (95%CI)a

–

3.32 (2.24–4.91)

4.75 (3.36–6.72)

6.97 (5.09–9.54)

–

 Unadjusted Model

4.47 (2.28–8.78)**

Ref.

1.43 (0.85–2.41)

2.05 (1.24–3.40)*

0.005

 Adjusted Model 1b

3.86 (1.99–7.48)**

Ref.

1.39 (0.82–2.35)

2.08 (1.25–3.44)*

0.004

 Adjusted Model 2c

2.90 (1.40–6.01)*

Ref.

1.28 (0.74–2.21)

2.00 (1.13–3.55)*

0.020

Nondiabetic cohort (N = 1322)

     

 Event

–

32

31

51

–

 Incidence rate (95%CI)a

–

2.72 (1.92–3.84)

2.57 (1.81–3.66)

4.39 (3.34–5.77)

–

 Unadjusted Model

2.23 (1.24–4.01)*

Ref.

0.95 (0.58–1.56)

1.61 (1.03–2.51)*

0.026

 Adjusted Model 1b

1.64 (0.98–2.74)

Ref.

1.04 (0.97–1.70)

1.57 (1.01–2.45)*

0.038

 Adjusted Model 2c

0.97 (0.56–1.69)

Ref.

0.91 (0.54–1.53)

1.21 (0.75–1.97)

0.386

Cardiovascular death

     

Overall cohort (N = 2111)

     

 Event

–

38

41

75

–

 Incidence rate (95%CI)a

–

1.97 (1.43–2.70)

2.18 (1.61–2.96)

4.36 (3.47–5.46)

–

 Unadjusted Model

3.88 (2.35–6.39)**

Ref.

1.10 (0.71–1.72)

2.17 (1.46–3.20)**

 < 0.001

 Adjusted Model 1b

2.90 (1.84–4.57)**

Ref.

1.15 (0.74–1.79)

2.16 (1.46–3.20)**

 < 0.001

 Adjusted Model 2c

1.85 (1.12–3.05)*

Ref.

1.01 (0.64–1.60)

1.82 (1.19–2.79)*

0.004

Diabetic cohort (N = 789)

     

 Event

–

19

20

33

–

 Incidence rate (95%CI)a

–

2.52 (1.61–3.95)

2.97 (1.92–4.60)

5.90 (4.19–8.29)

–

 Unadjusted Model

5.61 (2.58–12.17)**

Ref.

1.16 (0.62–2.18)

2.23 (1.27–3.93)*

0.004

 Adjusted Model 1b

4.92 (2.30–10.51)**

Ref.

1.15 (0.61–2.15)

2.26 (1.28–3.99)*

0.004

 Adjusted Model 2c

3.28 (1.43–7.57)*

Ref.

1.09 (0.56–2.09)

2.09 (1.10–3.98)*

0.026

Nondiabetic cohort (N = 1322)

     

 Event

–

19

21

42

–

 Incidence rate (95%CI)a

–

1.61 (1.03–2.53)

1.74 (1.14–2.67)

3.61 (2.67–4.89)

–

 Unadjusted Model

3.25 (1.65–6.41)**

Ref.

1.08 (0.58–2.01)

2.22 (1.29–3.81)*

0.002

 Adjusted Model 1b

2.24 (1.24–4.07)*

Ref.

1.17 (0.63–2.19)

2.17 (1.26–3.74)*

0.003

 Adjusted Model 2c

1.14 (0.60–2.16)

Ref.

1.06 (0.55–2.02)

1.60 (0.89–2.90)

0.097

  1. *P < 0.05; **P < 0.001
  2. aIncidence rate was calculated using the total number of deaths during the observational period divided by person-years at risk
  3. bModel 1 included age and sex
  4. cModel 2 included age, sex, current smoker, comorbidities (hypertension, diabetes, dyslipidemia, CKD, HF, and MI), STEMI, Killip > I, primary PCI, peak TnT, CRP, serum creatinine, LVEF, as well as medications (aspirin, ACEI/ARB/ARNI, β-blocker)
  5. CKD chronic kidney disease, CRP C-reactive protein, HF heart failure, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, SII systemic immune-inflammation index
  6. The bold value represents the statistical significance of 'P for trend' (P for trend<0.05) in the fully-adjusted model
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840